This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Following up on Pliant's PLN-74809 after the Phase 2a readout in IPF
Ticker(s): PLRXWho's the expert?
Institution: National Jewish Health
- Associate Professor of Pulmonary Sciences & Director of Interstitial Lung Disease program at National Jewish Health
- Manages 80 patients with IPF.
- Research focuses on Interstitial Lung Diseases and specifically on those related to autoimmune diseases.
Interview Goal This conversation will focus on the Phase 2a readout of PLN-74809, a dual-selective inhibitor of αvβ6 and αvβ1.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
